Clinical Trial Update: A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 neoadjuvant trial evaluating adding bevacizumab to trastuzumab and docetaxel in early-stage HER2-positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED